OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo
OncoMed Pharmaceuticals announced interim results from its ongoing Phase 1b trial investigating navicixizumab, OncoMed's anti-DLL4/VEGF bispecific antibody, in combination with paclitaxel in patients with platinum-resistant ovarian cancer. The patients had received a median of four prior therapies, all of whom had received prior paclitaxel and 69% had received prior bevacizumab. 22 of the 26 patients treated with the novel regimen experienced clinical benefit. Notably 11 of the 26 patients achieved a partial response and the median progression-free survival was 5.4 months. Historical response rates for patients with heavily pretreated platinum-resistant ovarian cancer treated with chemotherapy are typically 15% or less. The ongoing Phase 1b multicenter, open-label, dose-escalation and expansion trial is designed to assess the safety, preliminary efficacy, immunogenicity, pharmacokinetics and biomarker effects of navicixizumab plus paclitaxel. The trial has been expanded to enroll up to 60 patients with platinum-resistant ovarian cancer who have previously received bevacizumab and/or have failed at least two prior therapies.